09.11.2025, 1443 Zeichen

AT&S: In comparison to the prior-year period, consolidated revenue of AT&S increased by 6% to € 846 million in the first half of 2025/26 (PY: € 800 million). Adjusted for currency effects, consolidated revenue rose by 11%. Due to a positive volume development, AT&S was able to successfully counter both the ongoing price pressure and negative exchange rate effects during the reporting period.   EBITDA improved by 11% from € 157 million to € 175 million ‒ adjusted for currency effects, the increase amounted to 18%. The earnings improvement is primarily due to higher volumes. Despite the positive development, AT&S will continue to intensively pursue its comprehensive cost optimization and efficiency program in order to counter effects such as price pressure and inflation resulting from the persisting difficult market environment. In addition to price pressure, start-up costs in Kulim, Malaysia, and Leoben, Austria, had a negative impact on earnings. The EBITDA margin amounted to 20.6%, exceeding the prior-year level of 19.6%. “Despite massive foreign exchange headwinds and a challenging market environment, we were able to increase revenue and EBITDA and exceeded the half-year forecast,” says AT&S CEO Michael Mertin. AT&S is a leading global manufacturer of high-end IC substrates and printed circuit boards.
AT&S: weekly performance: -14.57%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (04/11/2025)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice: ATX TR zum 35er heute mit schnellstem 1000er-Marken-Sprung ever und der WBI ist über 2000!

Bildnachweis

Aktien auf dem Radar:UBM, Polytec Group, Amag, RHI Magnesita, Austriacard Holdings AG, SBO, ATX, ATX Prime, ATX TR, ATX NTR, Bawag, Mayr-Melnhof, Lenzing, voestalpine, Frequentis, Rosgix, AT&S, Palfinger, OMV, Kapsch TrafficCom, Agrana, Gurktaler AG VZ, SW Umwelttechnik, Wolford, Warimpex, Zumtobel, Pierer Mobility, FACC, Addiko Bank, Marinomed Biotech, Oberbank AG Stamm.

---